Zepbound and Mounjaro are the same molecule (tirzepatide) from Eli Lilly — but differ in FDA indication, self-pay options, and cost. Here's the breakdown.
| Zepbound® | Mounjaro® | |
|---|---|---|
| Maker | Eli Lilly | Eli Lilly |
| Active ingredient | Tirzepatide | Tirzepatide |
| FDA indication | Chronic weight management (+ OSA) | Type 2 diabetes |
| Mechanism | Dual GLP-1/GIP | Dual GLP-1/GIP |
| Self-pay / month | $299–$449 (LillyDirect) | ~$900–$1,080 (retail/GoodRx) |
| Retail list | ~$1,086 | ~$1,069–$1,080 |
| Weight-loss use | On-label | Off-label |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
Both contain tirzepatide and act on the same dual GLP-1/GIP pathway. Zepbound is FDA-approved for chronic weight management (and obstructive sleep apnea); Mounjaro is FDA-approved for type 2 diabetes. Using Mounjaro for weight loss is off-label.
Both are manufactured by Eli Lilly. Zepbound has a dedicated LillyDirect self-pay vial program ($299–$449/mo within the 45-day refill window); Mounjaro does not, so cash-pay relies on retail and GoodRx (~$900–$1,080). For compounded tirzepatide cost context, see compounded tirzepatide cost (not FDA-approved).
Zepbound is the on-label brand choice for weight management with the cheaper self-pay route. Mounjaro is the on-label choice for type 2 diabetes. Same molecule either way; a licensed clinician decides what is appropriate.
Both contain tirzepatide and work identically. The difference is FDA indication (Zepbound for weight, Mounjaro for type 2 diabetes) and the resulting pricing/coverage. See NexLife pricing
For weight management, Zepbound's LillyDirect self-pay ($299–$449/mo) is usually cheaper than cash-pay Mounjaro (~$900–$1,080/mo).
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.